HIF activation identifies early lesions in VHL kidneys

Breiteneder-Geleff, 1999, Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries, Am. J. Pathol., 154, 385, 10.1016/S0002-9440(10)65285-6 Brown, 1992, Vascular permeability factor mRNA and protein expression in human kidney, Kidney Int., 42, 1457, 10.1038/ki.1992.441 Bruick, 2001, A conserved family of prolyl-4-Hydroxylases that modify HIF, Science, 294, 1337, 10.1126/science.1066373 Clark, 1996, Hepatocyte growth factor/scatter factor and its receptor c-met, J. Endocrinol., 151, 459, 10.1677/joe.0.1510459 de Paulsen, 2001, Role of transforming growth factor-α in von Hippel-Lindau (VHL)(−/−) clear cell renal carcinoma cell proliferation, Proc. Natl. Acad. Sci. USA, 98, 1387 Ebert, 1995, Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences, J. Biol. Chem., 270, 29083, 10.1074/jbc.270.49.29083 Elson, 2001, Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α, Genes Dev., 15, 2520, 10.1101/gad.914801 Epstein, 2001, C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation, Cell, 107, 43, 10.1016/S0092-8674(01)00507-4 Ezaki, 1990, A new approach for identification of rat lymphatic capillaries using a monoclonal antibody, Arch. Histol. Cytol., 53, 77, 10.1679/aohc.53.Suppl_77 Foster, 1994, Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Hum. Mol. Genet., 3, 2169, 10.1093/hmg/3.12.2169 Gnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat. Genet., 7, 85, 10.1038/ng0594-85 Haase, 2001, Consequences of conditional inactivation of the VHL tumor suppressor in the murine renal cortex, JASN, 12, A2870 Hakem, 2001, Animal models of tumor-suppressor genes, Annu. Rev. Genet., 35, 209, 10.1146/annurev.genet.35.102401.090432 Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Hiraki, 1988, Growth factors rapidly induce expression of the glucose transporter gene, J. Biol. Chem., 263, 13655, 10.1016/S0021-9258(18)68291-2 Hise, 1996, Transforming growth factor-α expression in human renal cell carcinoma, Urology, 47, 29, 10.1016/S0090-4295(99)80377-X Iliopoulos, 1995, Tumour supression by the human von Hippel-Lindau gene product, Nat. Med., 1, 822, 10.1038/nm0895-822 Iliopoulos, 1998, pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation, Proc. Natl. Acad. Sci. USA, 95, 11661, 10.1073/pnas.95.20.11661 Ivan, 2001, HIFα targeted for VHL-mediated destruction by proline hydroxylation, Science, 292, 464, 10.1126/science.1059817 Ivanov, 1998, Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes, Proc. Natl. Acad. Sci. USA, 95, 12596, 10.1073/pnas.95.21.12596 Iyer, 1997, Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α, Genes Dev., 12, 149, 10.1101/gad.12.2.149 Jaakkola, 2001, Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 Kinzler, 1996, Lessons from hereditary colorectal cancer, Cell, 87, 159, 10.1016/S0092-8674(00)81333-1 Kinzler, 1997, Gatekeepers and caretakers, Nature, 386, 761, 10.1038/386761a0 Knudson, 2000, Chasing the cancer demon, Annu. Rev. Gen., 34, 1, 10.1146/annurev.genet.34.1.1 Kondo, 2001, The von Hippel-Lindau tumor suppressor gene, Exp. Cell Res., 264, 117, 10.1006/excr.2000.5139 Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 Liao, 1997, Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney, Cancer Res., 57, 2827 Maxwell, 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, 399, 271, 10.1038/20459 Maxwell, 2001, Activation of the HIF pathway in cancer, Curr. Opin. Genet. Dev., 11, 293, 10.1016/S0959-437X(00)00193-3 Motzer, 1996, Renal-cell carcinoma, N. Engl. J. Med., 335, 865, 10.1056/NEJM199609193351207 Nouwen, 1994, Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat, Lab. Invest., 70, 479 Ohh, 1998, The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix, Mol. Cell, 1, 959, 10.1016/S1097-2765(00)80096-9 Paal, 1998, A clinicopathologic and immunohistochemical study of ten pancreatic lymphangiomas and a review of the literature, Cancer, 82, 2150, 10.1002/(SICI)1097-0142(19980601)82:11<2150::AID-CNCR9>3.0.CO;2-Z Pastorekova, 1992, A novel quasi-viral agent, Ma Tu, is a two-component system, Virology, 187, 620, 10.1016/0042-6822(92)90464-Z Pause, 1998, The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit on serum withdrawal, Proc. Natl. Acad. Sci. USA, 95, 993, 10.1073/pnas.95.3.993 Porter, 2001, Molecular markers of tumor initiation and progression, Curr. Opin. Genet. Dev., 11, 60, 10.1016/S0959-437X(00)00157-X Salido, 1989, In situ hybridization of prepro-epidermal growth factor mRNA in the mouse kidney, Am. J. Physiol., 256, F632 Schoenfeld, 1998, A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor, Proc. Natl. Acad. Sci. USA, 95, 8817, 10.1073/pnas.95.15.8817 Schoenfeld, 2000, The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis, Oncogene, 19, 5851, 10.1038/sj.onc.1203985 Semenza, 2000, Hypoxia, clonal selection, and the role of HIF-1 in tumor progression, Crit. Rev. Biochem. Mol. Biol., 35, 71, 10.1080/10409230091169186 Shih, 2001, Top-down morphogenesis of colorectal tumors, Proc. Natl. Acad. Sci. USA, 98, 2640, 10.1073/pnas.051629398 Sikri, 1981, Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immuno-electron microscopical techniques, J. Anat., 132, 597 Talks, 2000, The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages, Am. J. Path., 157, 411, 10.1016/S0002-9440(10)64554-3 Waldherr, 1985, Co-expression of cytokeratin and vimentin intermediate-sized filaments in renal cell carcinomas. Comparative study of the intermediate-sized filament distribution in renal cell carcinomas and normal human kidney, Virchows Arch., 408, 15, 10.1007/BF00739959 Wallace, 1972, Renal tubular antigens in kidney tumors, Cancer, 29, 977, 10.1002/1097-0142(197204)29:4<977::AID-CNCR2820290444>3.0.CO;2-P Wu, 2001, Mouse models for multistep tumorigenesis, Trends Cell Biol., 11, S2, 10.1016/S0962-8924(01)82000-6 Wykoff, 2000, Hypoxia inducible expression of tumor associated carbonic anhydrases, Cancer Res., 60, 7075 Yu, 2001, HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation, Proc. Natl. Acad. Sci. USA, 98, 9630, 10.1073/pnas.181341498